Skip to main content

Pediatric Antibacterial and Antifungal Trials From 2007 to 2017.

Publication ,  Journal Article
Thaden, JT; Chiswell, K; Jaffe, I; Bergin, SP; Yang, WE; Romaine, A; Roberts, J; Nambiar, S; Farley, J; Benjamin, DK; Smith, PB; Tsalik, EL
Published in: Pediatrics
September 2018

BACKGROUND AND OBJECTIVES: The impact of the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) on pediatric antibacterial or antifungal drug trials is unknown. Our objective was to identify and characterize trials conducted under the BPCA and/or the PREA. METHODS: Pediatric antibacterial and antifungal drug trials with industry or US federal funding registered in clinicaltrials.gov from 2007 to 2017 were identified. Those conducted under BPCA and/or PREA were identified through US Food and Drug Administration and National Institute of Child Health and Human Development databases. RESULTS: Of 17 495 pediatric trials registered on clinicaltrials.gov between October 2007 and September 2017, 122 systemic antibacterial or antifungal drug trials with industry or US federal funding were identified. Of these 122 trials, 98 (80%) involved antibacterials only, 23 (19%) antifungals only, and 1 (1%) both antibacterials and antifungals. These represented <1% (122 of 17 495) of pediatric trials. Neither pediatric antibacterial nor antifungal drug trials commonly enrolled neonates 0 to 30 days old (30% [30 of 99] vs 42% [10 of 24], respectively). Pediatric antibacterial and antifungal trials were commonly industry funded (79% [78 of 99] and 83% [20 of 24], respectively). In total, 65% (79 of 122) of pediatric antibacterial and/or antifungal drug trials were conducted under BPCA and/or PREA. Researchers in trials conducted under BPCA and/or PREA, relative to non-BPCA and/or PREA trials, more often collected pharmacokinetic data (70% [55 of 79] vs 26% [11 of 43]). CONCLUSIONS: Although the majority of pediatric antibacterial and/or antifungal drug trials were conducted under BPCA and/or PREA, the overall number was low. Greater effort is needed to stimulate such trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pediatrics

DOI

EISSN

1098-4275

Publication Date

September 2018

Volume

142

Issue

3

Location

United States

Related Subject Headings

  • United States
  • Pediatrics
  • Humans
  • Drug Industry
  • Communicable Diseases
  • Clinical Trials as Topic
  • Child
  • Antifungal Agents
  • Anti-Bacterial Agents
  • 52 Psychology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thaden, J. T., Chiswell, K., Jaffe, I., Bergin, S. P., Yang, W. E., Romaine, A., … Tsalik, E. L. (2018). Pediatric Antibacterial and Antifungal Trials From 2007 to 2017. Pediatrics, 142(3). https://doi.org/10.1542/peds.2017-1849
Thaden, Joshua T., Karen Chiswell, Ian Jaffe, Stephen P. Bergin, William E. Yang, Andrew Romaine, Jamie Roberts, et al. “Pediatric Antibacterial and Antifungal Trials From 2007 to 2017.Pediatrics 142, no. 3 (September 2018). https://doi.org/10.1542/peds.2017-1849.
Thaden JT, Chiswell K, Jaffe I, Bergin SP, Yang WE, Romaine A, et al. Pediatric Antibacterial and Antifungal Trials From 2007 to 2017. Pediatrics. 2018 Sep;142(3).
Thaden, Joshua T., et al. “Pediatric Antibacterial and Antifungal Trials From 2007 to 2017.Pediatrics, vol. 142, no. 3, Sept. 2018. Pubmed, doi:10.1542/peds.2017-1849.
Thaden JT, Chiswell K, Jaffe I, Bergin SP, Yang WE, Romaine A, Roberts J, Nambiar S, Farley J, Benjamin DK, Smith PB, Tsalik EL. Pediatric Antibacterial and Antifungal Trials From 2007 to 2017. Pediatrics. 2018 Sep;142(3).

Published In

Pediatrics

DOI

EISSN

1098-4275

Publication Date

September 2018

Volume

142

Issue

3

Location

United States

Related Subject Headings

  • United States
  • Pediatrics
  • Humans
  • Drug Industry
  • Communicable Diseases
  • Clinical Trials as Topic
  • Child
  • Antifungal Agents
  • Anti-Bacterial Agents
  • 52 Psychology